Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Inclusion Criteria

• •Patients must have histologically confirmed advanced (International Federation of Gynecologists and Obstetricians \[FIGO\] stage III or IV), persistent, or recurrent endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy; histologic documentation of the recurrence is not required
• •All patients must have measurable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be \>= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or \>= 10 mm when measured by spiral CT
• •Patients must have at least one "target lesion" to be used to assess response, as defined by Response Evaluation Criteria In Solid Tumors (RECIST); tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented
• •Prior chemoradiotherapy for a pelvic recurrence is permitted; prior chemotherapy in the adjuvant setting for stage I, II, or III disease is permitted
• •* Note: no prior chemotherapy in the setting of stage IV disease is permitted unless the patient was without evidence of disease at the completion of chemotherapy and had at least six months of progression-free survival since the completion of chemotherapy
• •* Regardless of circumstances, no more than one prior chemotherapy regimen (including chemoradiotherapy) is permitted
• •Patient must be able to take p.o. medications
• •Performance status must be 0-2
• •Absolute neutrophil count \>= 1,500/mcL
• •Platelets \>= 100,000/mcL
• •Total bilirubin within normal institutional limits
• •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2.5 times institutional upper limit of normal v 3.0 (=\< 5 times upper limit of normal \[ULN\] for subjects with liver metastases)
• •Alkaline phosphatase =\< 2.5 times institutional upper limit of normal v 3.0 (=\< 5 times ULN for subjects with liver metastases)
• •Creatinine =\< 1.5 times normal institutional upper limit of normal
• •Cholesterol =\< 350 mg/dL (fasting)
• •Triglycerides =\< 400 mg/dL (fasting)
• •Albumin \>= 3.0 mg/dL
• •At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: hysterectomy, resection of a lung nodule-minor: a Port-A-Cath placement)
• •Patients who have met the pre-entry requirements
• •Patients must have signed an approved informed consent including Health Insurance Portability and Accountability Act (HIPAA) authorization